Jessica M Weaver

US Patent:

20130089594, Apr 11, 2013

Filed:

Apr 12, 2011

Appl. No.:

13/641034

Inventors:

Cheryl Stabler Anderson - Coral Gables FL, US
Eileen Pedraza - Coral Gables FL, US
Christopher A. Fraker - Hollywood FL, US
Peter Buchwald - Weston FL, US
Norma Sue Kenyon - Miami FL, US
Luca Inverardi - Miami Beach FL, US
Antonello Pileggi - Aventura FL, US
Paul Latta - Miami FL, US
Jeffrey Hubbell - Preverenges, CH
Jessica Weaver - Miami FL, US
Camillo D. Ricordi - Miami FL, US

Assignee:

CONVERGE BIOTECH INC. - Miami FL
UNIVERSITY OF MIAMI - Miami FL

International Classification:

A61L 27/18
A61L 27/26

US Classification:

424423, 424 937, 424400

Abstract:

The present invention provides highly porous, biocompatible and biostable scaffold constructs for improving overall cell engraftment, survival, function and long-term viability. These scaffolds can provide mechanical protection to implanted cells, afford retrievability from a subject, and allow for both intra-device vascularization and a means to spatially distribute the cells within the device. The scaffold surface or material may be modified with one or more different adhesion proteins and optionally other biological factors for enhanced cell adherence and viability. Further, the scaffold surface or material may be modified with one or more agents with slow/sustained release characteristics to aid engraftment, survival, function or long-term viability. Implanted cells of the invention may be insulin-producing cells such as islets.

US Patent:

20210146010, May 20, 2021

Filed:

Nov 18, 2020

Appl. No.:

16/951452

Inventors:

Jessica Weaver - Tempe AZ, US
Alec McCall - Tempe AZ, US
Sarah Brady - Tempe AZ, US

Assignee:

Arizona Board of Regents on behalf of Arizona State University - Tempe AZ

International Classification:

A61L 27/52
C12N 5/071
A61L 27/54
A61L 27/38
A61L 27/18
B29C 45/26

Abstract:

Provided herein is a cell macroencapsulation device composed of hydrogel in a 3D conformation that optimizes encapsulated cell viability and function when transplanted into a vascularized tissue space. The hydrogel macroencapsulation device is intended to reduce or eliminate immune response to the cell graft, while allowing exchange of encapsulated cell-secreted products, such as insulin. Also described herein is an injection-mold and fabrication process to generate the hydrogel macroencapsulation devices for use in the clinic.